The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

We present a case of unilateral, secondary open-angle glaucoma due to an underlying diffuse iris melanoma. The patient was referred by his ophthalmologist with uncontrolled, elevated intraocular ...

Mayo Clinic's organoids, microscopic versions of organs that function like the real ones, have been used by doctors to study ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

ROCHESTER, Minnesota — Mayo Clinic researchers have developed  organoid models  to study  uveal melanoma , one of the most common types of eye cancer ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this ...

D models of uveal melanoma are transforming cancer research, enabling personalized treatments and better drug testing for ...

Detailed price information for Delcath Systems Inc (DCTH-Q) from The Globe and Mail including charting and trades.

After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...